NEFL and amyotrophic lateral sclerosis: ,19 During the initial placebo-controlled phase I-III trial, a significant reduction of neurofilament light chain (NfL) in plasma compared to placebo suggested a disease-modifying effect,19 although clinical progression parameters such as ALS functional rating scale revised (ALSFRS-R) did not reach statistical significance after six months.19